>MAXY – But I wouldn't invest in any company with Howard as CEO. He talks the talk, but doesn't walk the walk.>
I’ve never thought MAXY was cheap enough to pull the trigger, but I think they are interesting enough to follow (although somewhat less interesting without the FVIIa program).
I’m especially curious to see what becomes of Maxy-Alpha for HCV.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”